← Back to Search

Education Intervention for Lung Cancer Screening Compliance (QLC+ Trial)

N/A
Recruiting
Research Sponsored by Nicole Ezer, MD, FRCPC, MPH
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
COPD aim: diagnosed with COPD, symptomatic (mMRC >=1 or CAT>= 10) and untreated, or not on first line guideline recommended therapy for COPD
Cardiovascular aim: mild to severe CAC identified on low dose CT, not on guideline recommended lipid-lowering therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year post ct
Awards & highlights

QLC+ Trial Summary

This trial tested if an educational intervention improves medication adherence in COPD and cardiovascular patients, leading to better health outcomes.

Who is the study for?
This trial is for individuals who have been screened for lung cancer and found to have mild to severe coronary artery calcification (CAC) without being on recommended lipid-lowering therapy, or diagnosed with symptomatic COPD not treated with first-line therapies. It's not suitable for those already on appropriate COPD treatment, without CAC, with known heart issues, diabetes, or a high suspicion of lung cancer.Check my eligibility
What is being tested?
The study tests if providing educational materials and treatment recommendations can improve adherence to medication guidelines at 12 months in patients with untreated COPD and cardiovascular disease within a lung cancer screening program.See study design
What are the potential side effects?
Since the intervention involves educational material rather than medications or invasive procedures, there are no direct side effects associated with it. However, changes in medication adherence as a result of education may lead to typical drug-related side effects.

QLC+ Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have COPD, experience symptoms, and am not on first-line treatment.
Select...
I have mild to severe artery plaque and am not on cholesterol-lowering medication.

QLC+ Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year post ct
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year post ct for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Guideline concordant inhaler therapy 1 year following the first low dose CT scan
X-Ray Computed Tomography
Secondary outcome measures
Absenteeism and presenteeism
Chronic Obstructive Airway Disease
Health Care Utilisation
+5 more

QLC+ Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Intervention Arm: CVDExperimental Treatment1 Intervention
Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy. CAC score obtained from lung cancer screening CT Scan images
Group II: Intervention Arm: COPDExperimental Treatment1 Intervention
Patients with untreated COPD or not on first line guideline recommended therapy.
Group III: Control Arm: CVDActive Control1 Intervention
Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy. Coronary artery Calcification (CAC) score obtained from lung cancer screening CT Scan images
Group IV: Control Arm: COPDActive Control1 Intervention
Patients with untreated COPD or not on first line guideline recommended therapy.

Find a Location

Who is running the clinical trial?

Nicole Ezer, MD, FRCPC, MPHLead Sponsor
1 Previous Clinical Trials
100 Total Patients Enrolled

Media Library

Intervention Arm: COPD Clinical Trial Eligibility Overview. Trial Name: NCT05444062 — N/A
Chronic Obstructive Pulmonary Disease Research Study Groups: Control Arm: CVD, Intervention Arm: COPD, Intervention Arm: CVD, Control Arm: COPD
Chronic Obstructive Pulmonary Disease Clinical Trial 2023: Intervention Arm: COPD Highlights & Side Effects. Trial Name: NCT05444062 — N/A
Intervention Arm: COPD 2023 Treatment Timeline for Medical Study. Trial Name: NCT05444062 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there spaces available for volunteers to join this trial?

"The clinical trial database indicates that this medical research project is still accepting applicants. Its inception date was April 23rd 2023 and it was most recently amended on July 20th of the same year."

Answered by AI

Are participants of this clinical trial restricted to individuals aged 25 and below?

"This medical trial stipulates that all participants must fall within the range of 55 to 74 years old."

Answered by AI

How many participants have been recruited to this research program?

"Affirmative. According to the data found on clinicaltrials.gov, this medical trial is actively trying to recruit participants; it was first posted April 23rd 2023 and last modified by July 20th of the same year. 330 patients are required for a single study site."

Answered by AI

To whom does this experimental process extend?

"To gain admittance into this medical trial, individuals must have chronic obstructive pulmonary disease and be within the ages of 55 to 74. Currently, 330 patients are being sought for recruitment purposes."

Answered by AI

What is the desired outcome of this experiment?

"This clinical trial will be evaluated over a year-long period post CT scan to determine if patients adhere to the prescribed inhaler therapy. Secondary objectives include monitoring medication possession ratio (MPR), measuring COPD symptoms with the validated COPD Assessment Test, and assessing quality of life using SF-36 questionnaire at baseline and 12 months post intervention."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Quebec Lung Cancer Screening PLUS Trial
Nicole Ezer, MD, FRCPC, MPH 2023. "Quebec Lung Cancer Screening PLUS Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05444062.
~220 spots leftby Sep 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top